Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonists are prescribed as an adjunct to diet and exercise for the management of type 2 diabetes, yet adherence to healthy nutrition and physical activity is often suboptimal. As the use of these agents continues to rise, there are some concerns about the negative aspects of associated weight loss, including loss of muscle mass. This article highlights the benefits of healthy nutrition and physical activity for type 2 diabetes management irrespective of GLP-1 receptor agonist use or associated weight loss, identifies barriers to healthy nutrition and physical activity, and provides guidance for primary care clinicians to further educate and advise their patients on these important topics when initiating GLP-1 receptor agonist treatment.